DBVT:NASDAQDBV Technologies S.A. Analysis
Data as of 2026-03-28 - not real-time
$20.00
Latest Price
8/10Risk
Risk Level: High
Executive Summary
DBV Technologies trades at $20, sitting below its 20‑day (20.9) and 50‑day (21.5) simple moving averages, with a neutral RSI of 46 and a bearish MACD histogram, suggesting short‑term downside pressure while volatility remains elevated at ~67% and beta is modest at 0.59. Valuation multiples are extreme – price‑to‑book >51× and price‑to‑sales >200× – and the company reports negative earnings, operating cash flow and free cash flow, underscoring a high‑risk, growth‑oriented profile.
The latest filings reveal a robust cash position of $194 million plus $94 million of recent financing, a debt load of only $7.7 million, and an advancing Viaskin® Peanut program targeting toddlers and children, with senior leadership bolstered for an upcoming BLA submission. Inclusion in the CAC Mid 60 and SBF 120 indices may improve visibility, but the combination of high cash burn, regulatory uncertainty and a thin trading volume (decreasing trend) keeps the risk profile elevated.
The latest filings reveal a robust cash position of $194 million plus $94 million of recent financing, a debt load of only $7.7 million, and an advancing Viaskin® Peanut program targeting toddlers and children, with senior leadership bolstered for an upcoming BLA submission. Inclusion in the CAC Mid 60 and SBF 120 indices may improve visibility, but the combination of high cash burn, regulatory uncertainty and a thin trading volume (decreasing trend) keeps the risk profile elevated.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 5/10
Key Factors
- Bearish MACD and price below short‑term SMAs
- Extreme valuation multiples with no earnings
- Decreasing volume indicating limited near‑term buying pressure
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- Strong cash runway ($288 M total) supporting continued R&D
- Progress toward BLA submission for Viaskin® Peanut
- Index inclusion (CAC Mid 60, SBF 120) potentially boosting liquidity and investor interest
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- Large unmet market for food‑allergy immunotherapy
- Platform potential across multiple allergens and indications
- Sustained cash resources offsetting current operating losses
Key Metrics & Analysis
Financial Health
Revenue Growth158.80%
P/E Ratio-68.7
ROE-234.14%
ROA-77.29%
Debt/Equity14.55
P/B Ratio51.8
Op. Cash Flow$-98260000
Free Cash Flow$-51063248
Industry P/E25.0
Technical Analysis
TrendNeutral
RSI46.0
Support$18.61
Resistance$24.05
MA 20$20.90
MA 50$21.54
MA 200$14.88
MACDBearish
VolumeDecreasing
Fear & Greed Index65.98
Valuation
Target Price$39.31
Upside/Downside96.57%
GradeOvervalued
TypeGrowth
Risk Assessment
Beta0.59
Volatility66.73%
Sector RiskHigh
Reg. RiskHigh
Geo RiskLow
Currency RiskMedium
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.